Kopetz S, Grothey A, Van Cutsem E, Yaeger R, et al. BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with
or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab
in BRAF V600E-mutant metastatic colorectal cancer. Ann Oncol 2019;30 Suppl 4:iv154.
PMID: 32085058